× Home Screening and diagnosis of type 2 diabetesGlycaemic monitoring and targets for type 2 diabetesLifestyle managementNon-insulin medicationsInsulinScreening and management of complications of diabetesManagement of cardiovascular risk factors in diabetesManagement of hypoglycaemiaSick day managementDiabetes in pregnancyDiabetes and drivingPrediabetesGo to the NZSSD site

Type 2 Diabetes Management Guidelines

GLP-1 receptor agonists (GLP1RA)

  • Special Authority Criteria
  • Patient has type 2 diabetes with diabetic renal disease (urinary albumin:creatinine ratio > 3 mg/mmol and/or eGFR < 60 mL/min), known cardiovascular disease or 5 year CVD risk > 15%
  • Type 2 diabetes with HbA1c > 53 mmol/mol despite maximal tolerated dose of metformin and/or alternative glucose lowering therapy for 6 months
  • The patient is not on a funded SGLT2i
  • Adverse effects of GLP1RA:
  • Nausea, vomiting, anorexia and diarrhoea – improves over time
  • Injection site reactions e.g. nodules
  • Pancreatitis (rare)
  • Myalgias and muscle weakness (rare)
  • Stevens-Johnson’s syndrome (rare)